After more than 30 years of scientific research de Faire Medical AB was founded in 2021with a clear Vision uncovering the full potential of applying microbial solutions to a specific organic substrate, and a unique technology of targeting bacterial strains into functional dietary supplements
Early observations that farmed animals suffering from intestinal inflammations recovered from eating fermented rice bran.
In late 1990s, a pro-/prebiotic dietary supplement for human uses was developed and safety studies designed as open case studies were initiated. No side effects or adverse reactions were detected as a single treatment or concomitantly with other commonly used drugs, i.e. anti-inflammatory, heart medicines, antibiotics and more.
In the early 2000 catalytic targeting of consortium for preferential metabolic actions was developed.
First study on alcohol digestion was conducted.
In 2020 an additional study on alcohol digestion and a study on Type 2 diabetes were conducted with most positive outcomes.
In February 2021 de Faire Medical AB was incorporated
Launch of Myrkl in the UK & Ireland